Medtronic's Record $88M Hernia Mesh Verdict and Affera Approval: What MDT Investors Need to Know

Medtronic ended the latest stretch with a courtroom loss and a regulatory win, and the combination gives investors a sharper view of the risks and opportunities in the company's strategy.

In August 2026, a federal jury ordered the medical-device maker to pay US$88 million in compensatory damages tied to injuries linked to Covidien hernia mesh. The award is one of the largest in this long-running product liability battle, and it adds to a legal overhang that Medtronic inherited when it acquired Covidien in 2015. While the company has argued that its mesh products are safe, the verdict is a reminder that product quality issues can carry a heavy financial price.

At almost the same time, Health Canada approved the Affera Integrated Mapping and Ablation System, which treats atrial fibrillation and atrial flutter. The system combines high-resolution mapping with pulsed field ablation, a newer technique that is gaining traction among electrophysiologists. The approval gives Medtronic a second PFA platform in Canada alongside PulseSelect. That matters because competition in this space is intensifying, and Medtronic is competing with Boston Scientific and Johnson & Johnson to capture a fast-growing share of cardiac ablation procedures.

For investors, the two events are not equal. The hernia mesh verdict is primarily a legacy issue. It can produce headline risk and legal costs, but it is unlikely to determine the company's earnings trajectory in the same way as the commercial ramp of its Cardiac Ablation Solutions portfolio. The more important signal may be Affera's regulatory momentum. The real test is execution: whether doctors adopt the system, whether procedure volumes expand, and whether Medtronic can avoid fresh product-quality concerns during the launch.

That execution risk is already reflected in the wide range of analyst forecasts. Medtronic's growth narrative implies revenue of US$41.5 billion and earnings of US$6.6 billion by fiscal 2029, which would require annual revenue growth of about 4.5%. More cautious scenarios put revenue near US$38.6 billion and earnings at roughly US$6.2 billion by 2029. The gap drives meaningful differences in valuation. Using the higher projection, fair value works out to about US$98.00 per share, roughly 7% above the current price. Some estimates run higher, suggesting the stock may be worth as much as 8% more than today's quote.

The $88 million verdict should not be dismissed. Legal exposure of that scale adds a layer of uncertainty, and if investor attention shifts from product cycles to liability risks, the stock could lose some of the premium it has earned from cardiac ablation optimism. But for now, the near-term earnings debate remains focused on execution. The Affera approval strengthens the lineup; the coming quarters will show whether Medtronic can turn that approval into durable procedure-driven growth.